[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Merani R, Sa-Ngiampornpanit T, Kerdraon Y, Billson F, McClellan KA: Euphorbia lactea sap keratouveitis: case report and review of the literature. Cornea; 2007 Jul;26(6):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A 79-year-old woman presented 34 hours after she felt some sap of an E. lactea plant spray into her right eye.
  • Examination revealed ciliary injection, 90% corneal epithelial defect, marked stromal edema with Descemet folds, and anterior-chamber flare with a 1-mm hypopyon.
  • No foreign body was seen on B scan ultrasound or computed tomography scan of the orbits.
  • Intensive topical antibiotic therapy was started with cephalothin 5% and gentamicin 0.9%, and the pupil was dilated with atropine.
  • [MeSH-major] Cornea / drug effects. Euphorbia / chemistry. Keratitis / chemically induced. Plant Extracts / adverse effects. Uveitis, Anterior / chemically induced
  • [MeSH-minor] Aged. Anti-Infective Agents / administration & dosage. Corneal Edema / chemically induced. Corneal Edema / drug therapy. Drug Therapy, Combination. Female. Humans. Visual Acuity / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592331.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Plant Extracts
  •  go-up   go-down


2. Tsilimbaris MK, Charisis SK, Naoumidi T, Panteleontidis V, Skondra D, Christodoulakis E, Naoumidi I: Contact transscleral ciliary body photodynamic therapy in pigmented rabbits using verteporfin and diode laser: evaluation of treatment parameters. Curr Eye Res; 2006 Jul-Aug;31(7-8):577-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contact transscleral ciliary body photodynamic therapy in pigmented rabbits using verteporfin and diode laser: evaluation of treatment parameters.
  • PURPOSE: To evaluate the treatment parameters necessary for achieving ciliary body photodynamic damage, enough to significantly reduce IOP, using verteporfin and a diode laser.
  • METHODS: The right eye ciliary body of 30 pigmented rabbits was irradiated using verteporfin (Visudyne) and a diode laser.
  • Animals were sacrificed 24 hours after the procedure and their eyes were evaluated by means of light and electron microscopy.
  • RESULTS: The therapy parameters that led to photodynamic effect avoiding thermal damage were laser power of 25 mW, irradiation time of 3 min per spot, and verteporfin dose of 1 mg/kg.
  • Transscleral ciliary body irradiation using these parameters resulted in vascular thrombosis of ciliary vessels and in substantial edema, resulting in separation of the two ciliary epithelium layers.
  • CONCLUSION: The combination of verteporfin and 690 nm diode laser is effective for the induction of ciliary body photodynamic damage, which results in significant but temporary IOP reduction, after transscleral PDT in pigmented rabbits.
  • [MeSH-major] Ciliary Body / drug effects. Laser Therapy. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. Porphyrins / pharmacology
  • [MeSH-minor] Animals. Follow-Up Studies. Intraocular Pressure / drug effects. Microscopy, Electron. Rabbits. Sclera. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877266.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


3. Birt CM: The use of topical ketorolac 0.5% for pain relief following cyclophotocoagulation. Ophthalmic Surg Lasers Imaging; 2003 Sep-Oct;34(5):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although usually successful, the procedure is often accompanied by pain.
  • PATIENTS AND METHODS: Thirty-six patients requiring a cyclodestructive procedure were randomized into two groups.
  • Each group received a standardized cycloablative laser procedure and routine postoperative drops.
  • There was a significant difference between the groups in the average and daily pain rating, with the ketorolac therapy group reporting significantly less pain.
  • CONCLUSION: The addition of topical ketorolac significantly lessened the pain reported by patients following a cyclodestructive laser procedure.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Ciliary Body / surgery. Ketorolac / therapeutic use. Laser Coagulation / adverse effects. Prednisolone / analogs & derivatives. Prednisolone / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Drug Therapy, Combination. Female. Glaucoma / surgery. Humans. Male. Middle Aged. Ophthalmic Solutions. Pain Measurement / methods. Pain, Postoperative / drug therapy. Pain, Postoperative / etiology. Prospective Studies. Safety. Treatment Outcome

  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14509461.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Ophthalmic Solutions; 8B2807733D / prednisolone acetate; 9PHQ9Y1OLM / Prednisolone; YZI5105V0L / Ketorolac
  •  go-up   go-down


Advertisement
4. Vladyka V, Liscák R, Simonová G, Pilbauer J, Hejduková I, Novácek L: Progress in glaucoma treatment research: a nonrandomized prospective study of 102 patients with advanced refractory glaucoma treated by Leksell gamma knife irradiation. J Neurosurg; 2005 Jan;102 Suppl:214-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in glaucoma treatment research: a nonrandomized prospective study of 102 patients with advanced refractory glaucoma treated by Leksell gamma knife irradiation.
  • OBJECT: The authors performed a study to characterize the effects of ciliary body gamma knife surgery (GKS) for advanced glaucoma.
  • Blind eyes received 20 Gy to the 50% isodose.
  • If there was preserved vision the dose was 15 Gy.
  • Treatment complications were slight.
  • Pharmacotherapy could be reduced in all patients and ceased in approximately one third.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ciliary Body / pathology. Ciliary Body / surgery. Disease Progression. Equipment Design. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pilot Projects. Prospective Studies. Radiation Dosage. Retinal Ganglion Cells / pathology. Visual Fields / physiology

  • Genetic Alliance. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Jul;103(1):192; author reply 192-3 [16121993.001]
  • (PMID = 15662813.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Vladyka V, Lis C Ák R, S Imonová G, Pilbauer J, Hejduková I, Novác Ek L: Progress in glaucoma treatment research: a nonrandomized prospective study of 102 patients with advanced refractory glaucoma treated by Leksell gamma knife irradiation. J Neurosurg; 2005 Jan;102(s_supplement):214-219
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in glaucoma treatment research: a nonrandomized prospective study of 102 patients with advanced refractory glaucoma treated by Leksell gamma knife irradiation.
  • OBJECT: The authors performed a study to characterize the effects of ciliary body gamma knife surgery (GKS) for advanced glaucoma.
  • Blind eyes received 20 Gy to the 50% isodose.
  • If there was preserved vision the dose was 15 Gy.
  • Treatment complications were slight.
  • Pharmacotherapy could be reduced in all patients and ceased in approximately one third.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306455.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ciliary body / gamma knife surgery / glaucoma
  •  go-up   go-down


6. Waki M, Yoshida Y, Oka T, Azuma M: Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res; 2001 Jun;22(6):470-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Contractility of ciliary muscle could be implicated in regulation of intraocular pressure while that of ocular vessels could affect blood flow to retina.
  • METHODS: An inhibitor of ROCK, Y-27632, was dissolved in an ophthalmic solution and topically administered to the eye of a Japanese white rabbit.
  • Constriction of ciliary muscle was measured by the Magnus method using 12 eyes.
  • RESULTS: Topical application of 0.1 and 0.03% Y-27632 significantly decreased the intraocular pressure, with maximum decreases of 5.3 and 4.3 mm Hg after 90 minutes compared with the control eye.
  • Y-27632 inhibited the carbachol-induced constriction of rabbit ciliary muscle.
  • The inhibitor relaxed the excised ciliary muscle which was previously constricted by carbachol suggesting that the inhibitor acts to increase the uveoscleral outflow.
  • Our results suggest that the ROCK inhibitor is a promising treatment for glaucoma therapy in the next generation.
  • [MeSH-major] Amides / pharmacology. Antihypertensive Agents / pharmacology. Enzyme Inhibitors / pharmacology. Intraocular Pressure / drug effects. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Pyridines / pharmacology
  • [MeSH-minor] Administration, Topical. Animals. Carbachol / pharmacology. Ciliary Body / drug effects. Intracellular Signaling Peptides and Proteins. Male. Muscle Contraction / drug effects. Muscle, Smooth / drug effects. Ophthalmic Solutions. Rabbits. Tonometry, Ocular. rho-Associated Kinases

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584347.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amides; 0 / Antihypertensive Agents; 0 / Enzyme Inhibitors; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ophthalmic Solutions; 0 / Pyridines; 138381-45-0 / Y 27632; 8Y164V895Y / Carbachol; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / rho-Associated Kinases
  •  go-up   go-down


7. Balestrazzi A, Blasi MA, Primitivo S, Balestrazzi E: Escherichia coli endophthalmitis after trans-scleral resection of uveal melanoma. Eur J Ophthalmol; 2002 Sep-Oct;12(5):437-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Escherichia coli endophthalmitis after trans-scleral resection of uveal melanoma.
  • PURPOSE: To report a case of Escherichia coli endophthalmitis after trans-scleral resection of an uveal melanoma.
  • METHODS: A large ciliary body melanoma was treated by trans-scleral resection and full-thickness sclerectomy because of epibulbar tumor extrusion, followed by adjuvant ruthenium plaque therapy.
  • RESULTS: Two months after treatment the patient developed wound dehiscence and consecutive endophthalmitis.
  • [MeSH-major] Ciliary Body. Endophthalmitis / microbiology. Escherichia coli Infections / etiology. Melanoma / surgery. Ophthalmologic Surgical Procedures / adverse effects. Uveal Neoplasms / surgery
  • [MeSH-minor] Aged. Anti-Bacterial Agents. Drug Therapy, Combination / therapeutic use. Female. Humans. Sclera / surgery

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12474930.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


8. Paskowitz DM, Donohue-Rolfe KM, Yang H, Yasumura D, Matthes MT, Hosseini K, Graybeal CM, Nune G, Zarbin MA, Lavail MM, Duncan JL: Neurotrophic factors minimize the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci; 2007 Jan;48(1):430-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotrophic factors minimize the retinal toxicity of verteporfin photodynamic therapy.
  • PURPOSE: A prior study showed that brain-derived neurotrophic factor (BDNF) rescues photoreceptors from collateral retinal damage caused by photodynamic therapy (PDT).
  • This study was conducted to determine whether ciliary neurotrophic factor (CNTF), a combination of BDNF and CNTF, or pigment epithelial cell-derived growth factor (PEDF) might protect photoreceptors and retinal function more effectively than BDNF.
  • Also investigated was whether protection would be observed after a second round of PDT with adjunctive BDNF treatment.
  • METHODS: Normal rats received intravitreal injections of BDNF, CNTF, a combination of BDNF and CNTF, or PEDF in one eye and PBS in the other 2 days before PDT.
  • Another group of rats received two courses of PDT 3 months apart, with injection of BDNF 2 days before each treatment.
  • Adjunctive treatment with BDNF also protects retinal structure and function through two rounds of PDT, suggesting its potential value for patients who require multiple treatments.
  • [MeSH-major] Nerve Growth Factors / therapeutic use. Neuroprotective Agents / therapeutic use. Photochemotherapy. Photoreceptor Cells, Vertebrate / drug effects. Photosensitizing Agents / toxicity. Porphyrins / toxicity. Retinal Diseases / prevention & control
  • [MeSH-minor] Animals. Brain-Derived Neurotrophic Factor / therapeutic use. Cell Survival / drug effects. Ciliary Neurotrophic Factor / therapeutic use. Drug Therapy, Combination. Electroretinography / drug effects. Eye Proteins / therapeutic use. Injections. Rats. Rats, Inbred BN. Retina / drug effects. Retina / physiology. Serpins / therapeutic use. Vitreous Body

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197564.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY00415; United States / NEI NIH HHS / EY / EY01919; United States / NEI NIH HHS / EY / EY02162; United States / NEI NIH HHS / EY / EY06842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Ciliary Neurotrophic Factor; 0 / Eye Proteins; 0 / Nerve Growth Factors; 0 / Neuroprotective Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Serpins; 0 / pigment epithelium-derived factor; 129497-78-5 / verteporfin
  •  go-up   go-down


9. van Emelen C, Goethals M, Dralands L, Casteels I: Treatment of glaucoma in children with Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus; 2000 Jan-Feb;37(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of glaucoma in children with Sturge-Weber syndrome.
  • BACKGROUND: Sturge-Weber syndrome is a rare congenital neuro-oculocutaneous disorder.
  • In 7 of 8 patients with glaucoma, topical pharmacotherapy (beta-blockers and carbonic anhydrase inhibitors) alone failed to normalize intraocular pressures.
  • In those patients, cryocoagulation of the ciliary body was performed.
  • CONCLUSIONS: Cryocoagulation of the ciliary body combined with topical medication is an effective and safe treatment option in the management of glaucoma in children with Sturge-Weber syndrome.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Carbonic Anhydrase Inhibitors / therapeutic use. Ciliary Body / surgery. Cryosurgery. Glaucoma / surgery. Sturge-Weber Syndrome / complications
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Drug Therapy, Combination. Eye Diseases / etiology. Female. Humans. Infant. Intraocular Pressure. Male. Retrospective Studies


10. Ritch R, Ishikawa H, Rothman R, Yu G, Liebmann JM: The efficacy of latanoprost is independent of the width of the ciliary body face. J Glaucoma; 2002 Jun;11(3):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of latanoprost is independent of the width of the ciliary body face.
  • PURPOSE: To assess the relation between the intraocular pressure-lowering efficacy of latanoprost 0.005% and the area of the ciliary body face exposed to the anterior chamber as assessed by ultrasound biomicroscopy.
  • CONCLUSION: Although latanoprost lowers intraocular pressure by enhancing uveoscleral outflow, its efficacy is independent of the height of the ciliary face.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Ciliary Body / anatomy & histology. Glaucoma, Open-Angle / drug therapy. Intraocular Pressure / drug effects. Prostaglandins F, Synthetic / therapeutic use
  • [MeSH-minor] Body Surface Area. Female. Humans. Male. Middle Aged. Ocular Hypertension / drug therapy. Ophthalmic Solutions. Prospective Studies

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12140402.001).
  • [ISSN] 1057-0829
  • [Journal-full-title] Journal of glaucoma
  • [ISO-abbreviation] J. Glaucoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Ophthalmic Solutions; 0 / Prostaglandins F, Synthetic; 6Z5B6HVF6O / latanoprost
  •  go-up   go-down


11. Pucci V, Tappainer F, Borin S, Bellucci R: Long-term follow-up after transscleral diode laser photocoagulation in refractory glaucoma. Ophthalmologica; 2003 Jul-Aug;217(4):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: Patients affected by glaucoma refractory to medical or surgical treatment are difficult to treat.
  • PATIENTS AND METHODS: One hundred and twenty eyes of 107 patients suffering from refractory glaucoma and treated with DLPC were followed at the Eye Clinic of Verona University for an average of 26 +/- 8 months.
  • RESULTS: A total of 207 treatments were given.
  • More than one treatment was given in 55 eyes (45.8%).
  • Mean total medications were reduced from 4.5 +/- 0.5 to 2.3 +/- 0.3.
  • No serious complications occurred in the 207 treatments.
  • It also served to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy.
  • This procedure is relatively safe, very fast and easy to learn.
  • However, careful attention is required to determine the exact position of the ciliary body in malformative glaucoma.
  • Multiple treatments may be required to control IOP.
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Anesthetics, Local / administration & dosage. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Injections. Intraocular Pressure. Intraoperative Complications. Lidocaine / administration & dosage. Male. Middle Aged. Pain / drug therapy. Pain / etiology. Reoperation. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • Hazardous Substances Data Bank. LIDOCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12792134.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anesthetics, Local; 98PI200987 / Lidocaine
  •  go-up   go-down


12. Valmaggia C, de Smet M: Endoscopic laser coagulation of the ciliary processes in patients with severe chronic glaucoma. Klin Monbl Augenheilkd; 2004 May;221(5):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic laser coagulation of the ciliary processes in patients with severe chronic glaucoma.
  • BACKGROUND: To investigate the effect of endoscopic laser coagulation on the ciliary processes in order to control intraocular pressure (IOP) in patients with severe chronic glaucoma.
  • Preoperatively, all patients had not responded to intensive glaucomatous topical and systemic treatment (mean 4.2 drugs, range 3 - 5).
  • After pars plana vitrectomy, the ciliary processes were coagulated under endoscopic view over 180 - 270 degrees using endolaser (argon green with spots of 300 - 500 mW for 0.4 - 0.5 s).
  • The postoperative IOP was over 1 year under 21 mm Hg in patient 1 with one topical drug, and in patients 2 and 3 without any further treatment.
  • Patient 4 needed trabeculectomy and one topical drug to control IOP.
  • The IOP was not controlled in patient 5 with the shortest follow-up despite additional topical treatment.
  • No serious treatment-related complication was noted.
  • CONCLUSIONS: Endoscopic laser coagulation allows a precise destruction of the ciliary processes, and permits a better control of IOP in certain cases of severe chronic glaucoma.
  • Further investigations are necessary to better evaluate this therapy.
  • [MeSH-major] Ciliary Body / surgery. Filtering Surgery. Glaucoma / surgery. Laser Coagulation. Ophthalmoscopy
  • [MeSH-minor] Aged. Chronic Disease. Combined Modality Therapy. Female. Humans. Intraocular Pressure / physiology. Male. Microsurgery. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / surgery. Reoperation. Trabeculectomy. Treatment Failure. Treatment Outcome. Vitrectomy


13. Abramson DH, Rollins IS, Lin A, Odell P, Folberg R: Tadalafil-induced subretinal and choroidal hemorrhage in a patient with an unsuspected uveal (choroidal and ciliary body) melanoma. Arch Ophthalmol; 2006 Jul;124(7):1058-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tadalafil-induced subretinal and choroidal hemorrhage in a patient with an unsuspected uveal (choroidal and ciliary body) melanoma.
  • [MeSH-major] Carbolines / adverse effects. Choroid Hemorrhage / chemically induced. Melanoma / ultrasonography. Phosphodiesterase Inhibitors / adverse effects. Retinal Hemorrhage / chemically induced. Uveal Neoplasms / ultrasonography
  • [MeSH-minor] Erectile Dysfunction / drug therapy. Eye Enucleation. Humans. Male. Middle Aged. Tadalafil

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TADALAFIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Ophthalmol. 2007 Mar;125(3):438. Dosage error in article text
  • (PMID = 16832036.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbolines; 0 / Phosphodiesterase Inhibitors; 742SXX0ICT / Tadalafil
  •  go-up   go-down


14. Augsten R, Königsdörffer E: [Surgical treatment of cyclodialysis]. Klin Monbl Augenheilkd; 2005 Jun;222(6):509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of cyclodialysis].
  • When treatment with cycloplegics or steroids is ineffective in attaching the ciliary body, cyclodialysis should be surgically treated.
  • However, for reliable diagnosis and surgical therapy, an exact identification (size and extent) of the cyclodialysis cleft is imperative.
  • CASE REPORT: Four patients (19 to 65 years old, mean 45 years) with a detached ciliary body are described.
  • The diagnosis was established with UBM.
  • In spite of an intense treatment with cycloplegics and steroids no reattachment of the cyclodialysis took place.
  • CONCLUSION: In cases where drug therapies are unsuccessful in attaching the ciliary body, an operative fixation is recommended.
  • UBM is a very useful tool for making an exact diagnosis and defining the location of cyclodialysis as well as for follow-up of surgical treatment.
  • [MeSH-major] Ciliary Body / injuries. Ciliary Body / surgery. Ophthalmologic Surgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Microscopy, Acoustic. Middle Aged. Mydriatics / administration & dosage. Steroids / administration & dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973631.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mydriatics; 0 / Steroids
  •  go-up   go-down


15. Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas ES: Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology; 2009 Nov;116(11):2206-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
  • PURPOSE: To examine whether interferon (IFN)-alfa-2a treatment after radiation or enucleation reduces death rates in patients with uveal melanoma.
  • PARTICIPANTS: Subjects were identified through the ocular oncology clinic of the Massachusetts Eye and Ear Infirmary.
  • Patients eligible for the study were at increased risk of metastasis because of the presence of at least one of the following characteristics: age >or=65 years, largest tumor diameter (LTD) >or=15 mm, ciliary body involvement of the tumor, or extrascleral tumor extension.
  • METHODS: Between May 1995 and June 1999, 121 patients with choroidal or ciliary body melanoma began a 2-year course of therapy (3 MIU IFN-alfa-2a subcutaneously 3 times per week), initiated within 3 years of primary therapy.
  • All patients underwent regular monitoring for drug toxicity.
  • To evaluate IFN-alfa-2a efficacy, we selected a series of historical controls frequency-matched (2:1) to IFN-alfa-2a-treated patients on age (+/-5 years), LTD (+/-3 mm), gender, and survival time between primary therapy and initiation of IFN therapy.
  • MAIN OUTCOME MEASURES: Melanoma-related mortality, metastasis, IFN-related toxicities.
  • RESULTS: Fifty-five patients (45%) completed therapy; the median dose for IFN-alfa-2a-treated patients was 792 MIU (85% of the theoretic dose).
  • The median follow-up time in the IFN-alfa-2a-treated group was approximately 9 years.
  • Treatment and control groups were similar with respect to age (P = 0.78), LTD (P = 0.38), and gender (P = 1.0).
  • Of 363 patients, 108 developed metastasis under observation; 42 of these were IFN-alfa-2a-treated patients.
  • Cumulative 5-year melanoma-related death rates were 17% in the radiation or enucleation-only group, 15% in those who completed the entire IFN-alfa-2a course, and 35% in those who discontinued IFN-alfa-2a therapy.
  • In multivariate Cox regression, IFN-alfa-2a had no significant influence on melanoma-related mortality (rate ratio = 1.02, 95% confidence interval, 0.68-1.5, P = 0.91) or all-cause mortality (rate ratio = 0.84, 95% confidence interval, 0.58-1.2, P = 0.34).
  • CONCLUSIONS: Interferon-alfa-2a has no material influence on survival in patients with choroidal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Eye Enucleation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Recombinant Proteins. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2010 Sep;117(9):1861 [20816255.001]
  • (PMID = 19744725.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


16. Cekiç O, Bardak Y, Tiğ SU, Demirkol A, Ekim MM, Altintaş O, Yeşildağ A, Oyar O: Hemodynamic response to intravitreal triamcinolone in eyes with macular edema: intravitreal triamcinolone and ocular blood flow. Int Ophthalmol; 2007 Oct;27(5):313-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compared to controls, a significant difference existed in the ophthalmic artery resistant index (P = 0.001) and end-diastolic velocity (P < 0.001) in diabetics.
  • At one month, compared to fellow eyes, change in end diastolic velocity from baseline in treated eyes was significantly decreased in posterior ciliary arteries (0.68 +/- 0.34 cm/s [mean +/- SEM] vs. -1.04 +/- 0.81 cm/s, P = 0.012).
  • In eyes with retinal vein occlusion, baseline CDI evaluation demonstrated reduced posterior ciliary arteries systolic flow velocity compared to fellow and control eyes (13.24 +/- 1.04 cm/s, 16.37 +/- 0.76 cm/s and 14.33 +/- 1.41 cm/s, respectively, P = 0.007).
  • Increased peak systolic velocity in the posterior ciliary arteries at one week (P = 0.02), one month (P = 0.005) and two months (P = 0.04), and increase in central retinal artery resistant index at one month was noted (P = 0.05).
  • CONCLUSION: Intravitreal triamcinolone temporarily changed central retinal artery blood flow and posterior ciliary arteries' peak systolic blood velocity in eyes with retinal vein occlusion whilst no response of blood flow to triamcinolone injection but only transiently altered end diastolic blood velocity in posterior ciliary arteries was observed in diabetic eyes.
  • [MeSH-major] Blood Flow Velocity / drug effects. Diabetic Retinopathy / drug therapy. Eye / blood supply. Glucocorticoids / administration & dosage. Macular Edema / drug therapy. Triamcinolone Acetonide / administration & dosage. Vascular Resistance / drug effects
  • [MeSH-minor] Aged. Diastole. Female. Humans. Injections. Male. Middle Aged. Ophthalmic Artery / physiopathology. Prospective Studies. Retinal Vein Occlusion / drug therapy. Retinal Vein Occlusion / physiopathology. Vitreous Body

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Diabetic Eye Problems.
  • MedlinePlus Health Information. consumer health - Eye Care.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 2006 Feb;90(2):198-201 [16424533.001]
  • [Cites] J Clin Endocrinol Metab. 1960 Mar;20:446-56 [14437204.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Aug;78(4):386-9 [10990037.001]
  • [Cites] Eye (Lond). 2006 Sep;20(9):1025-9 [16123781.001]
  • [Cites] Retina. 2005 Oct-Nov;25(7):851-5 [16205563.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1255-61 [16538448.001]
  • [Cites] J Clin Invest. 1991 Aug;88(2):385-9 [1650792.001]
  • [Cites] Retina. 2005 Oct-Nov;25(7):846-50 [16205562.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Apr;36(5):864-70 [7706034.001]
  • [Cites] J Hypertens. 1987 Dec;5(6):739-44 [3429873.001]
  • [Cites] Br J Ophthalmol. 2004 Sep;88(9):1131-6 [15317702.001]
  • [Cites] Cardiovasc Res. 1999 Jan;41(1):55-64 [10325953.001]
  • [Cites] Br J Ophthalmol. 1964 Apr;48:205-8 [14190432.001]
  • [Cites] Am J Ophthalmol. 2005 Nov;140(5):948-9 [16310489.001]
  • [Cites] J Clin Ultrasound. 2000 Jan;28(1):28-33 [10602102.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):50-3 [10209435.001]
  • [Cites] Br J Ophthalmol. 2002 Nov;86(11):1243-7 [12386080.001]
  • (PMID = 17505781.001).
  • [ISSN] 0165-5701
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glucocorticoids; F446C597KA / Triamcinolone Acetonide
  •  go-up   go-down


17. Borghi V, Bastia E, Guzzetta M, Chiroli V, Toris CB, Batugo MR, Carreiro ST, Chong WK, Gale DC, Kucera DJ, Jia L, Prasanna G, Ongini E, Krauss AH, Impagnatiello F: A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther; 2010 Apr;26(2):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In pharmacokinetic studies, NCX 125 and latanoprost resulted in similar latanoprost-free acid exposure in anterior segment ocular tissues.
  • This may lead to potential new perspectives in the treatment of patients at risk of glaucoma.
  • [MeSH-major] Antihypertensive Agents / pharmacology. Disease Models, Animal. Glaucoma / drug therapy. Intraocular Pressure / drug effects. Nitric Oxide / metabolism. Prostaglandins F, Synthetic / pharmacology. Prostaglandins, Synthetic / pharmacology
  • [MeSH-minor] Animals. Aqueous Humor / metabolism. Ciliary Body / metabolism. Cyclic GMP / metabolism. Dogs. Female. Iris / metabolism. Macaca fascicularis. Macrophages / drug effects. Macrophages / metabolism. Male. Nitric Oxide Synthase Type II / antagonists & inhibitors. Ocular Hypertension / drug therapy. Ocular Hypertension / metabolism. Ophthalmic Solutions / pharmacology. Rabbits. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415621.001).
  • [ISSN] 1557-7732
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-(nitrooxymethyl)-2-(nitrooxy)ethyl 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; 0 / Antihypertensive Agents; 0 / Ophthalmic Solutions; 0 / Prostaglandins F, Synthetic; 0 / Prostaglandins, Synthetic; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type II; H2D2X058MU / Cyclic GMP
  •  go-up   go-down






Advertisement